Maghin Edoardo, Garbati Patrizia, Quarto Rodolfo, Piccoli Martina, Bollini Sveva
Tissue Engineering Laboratory, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padua, Italy.
Department of Women's and Children Health, University of Padova, Padua, Italy.
Front Bioeng Biotechnol. 2020 May 13;8:447. doi: 10.3389/fbioe.2020.00447. eCollection 2020.
True cardiac regeneration of the injured heart has been broadly described in lower vertebrates by active replacement of lost cardiomyocytes to functionally and structurally restore the myocardial tissue. On the contrary, following severe injury (i.e., myocardial infarction) the adult mammalian heart is endowed with an impaired reparative response by means of meager wound healing program and detrimental remodeling, which can lead over time to cardiomyopathy and heart failure. Lately, a growing body of basic, translational and clinical studies have supported the therapeutic use of stem cells to provide myocardial regeneration, with the working hypothesis that stem cells delivered to the cardiac tissue could result into new cardiovascular cells to replenish the lost ones. Nevertheless, multiple independent evidences have demonstrated that injected stem cells are more likely to modulate the cardiac tissue via beneficial paracrine effects, which can enhance cardiac repair and reinstate the embryonic program and cell cycle activity of endogenous cardiac stromal cells and resident cardiomyocytes. Therefore, increasing interest has been addressed to the therapeutic profiling of the stem cell-derived (namely the total of cell-secreted soluble factors), with specific attention to cell-released extracellular vesicles, including exosomes, carrying cardioprotective and regenerative RNA molecules. In addition, the use of cardiac decellularized extracellular matrix has been recently suggested as promising biomaterial to develop novel therapeutic strategies for myocardial repair, as either source of molecular cues for regeneration, biological scaffold for cardiac tissue engineering or biomaterial platform for the functional release of factors. In this review, we will specifically address the translational relevance of these two approaches with interest in their feasibility to rejuvenate endogenous mechanisms of cardiac repair up to functional regeneration.
在低等脊椎动物中,受损心脏的真正心脏再生已被广泛描述,即通过主动替换丢失的心肌细胞来在功能和结构上恢复心肌组织。相反,在遭受严重损伤(即心肌梗死)后,成年哺乳动物心脏的修复反应受损,表现为伤口愈合程序微弱且伴有有害的重塑,随着时间的推移,这可能导致心肌病和心力衰竭。最近,越来越多的基础、转化和临床研究支持使用干细胞进行心肌再生,其工作假设是将干细胞输送到心脏组织中可产生新的心血管细胞以补充丢失的细胞。然而,多个独立证据表明,注射的干细胞更有可能通过有益的旁分泌作用调节心脏组织,这可以增强心脏修复并恢复内源性心脏基质细胞和驻留心肌细胞的胚胎程序及细胞周期活性。因此,人们对干细胞衍生产物(即细胞分泌的可溶性因子的总和)的治疗特性越来越感兴趣,尤其关注细胞释放的细胞外囊泡,包括携带心脏保护和再生RNA分子的外泌体。此外,最近有人提出使用心脏脱细胞细胞外基质作为有前景的生物材料,以开发用于心肌修复的新型治疗策略,它既可以作为再生的分子线索来源、心脏组织工程的生物支架,也可以作为因子功能释放的生物材料平台。在这篇综述中,我们将特别探讨这两种方法的转化相关性,关注它们激活心脏修复内源性机制直至实现功能再生的可行性。